#United States #oncology #IDEAYA Biosciences #South San Francisco #targeted therapeutics

IDEAYA Biosciences Set to Engage Investors in September 2025

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leader in precision medicine focusing on oncology, has announced its involvement in pivotal investor relations events scheduled for September 2025. These events promise to offer valuable insights into the company's strategic plans and pipeline developments.

Upcoming Investor Relations Events

Cantor Global Healthcare Conference 2025

• - Date: September 3, 2025
• - Time: 9:10 AM ET

The first event, taking place at the Cantor Global Healthcare Conference, will feature a fireside chat with Yujiro S. Hata, the President and CEO of IDEAYA. The discussion will be led by Li Watsek, a Biotechnology Analyst, ensuring an informative session for investors.

IDEAYA's 10-Year Anniversary R&D Day

• - Date: September 8, 2025
• - Time: 8:00 AM ET

This significant day marks IDEAYA's decade-long journey in the biotechnology sector. The company will host both in-person and virtual presentations, updating stakeholders on clinical data from its diverse pipeline. Highlights of the event will include insights from Dr. Arun D. Singh, a key opinion leader and Director at the Cole Eye Institute, Cleveland Clinic, who will be joined by IDEAYA's leadership team to discuss future growth catalysts.

Morgan Stanley 23rd Annual Global Healthcare Conference

• - Date: September 9, 2025

Management will engage in one-on-one meetings with investors, providing a platform for direct interaction and potential partnership discussions.

Accessing the Events Online

Investors keen to follow the proceedings can tune in through a live audio webcast, accessible via the IDEAYA Biosciences website in the 'Investors/Events' section. Recordings of the events will also be available for replay for up to 30 days, ensuring that stakeholders can catch up on any missed content.

About IDEAYA Biosciences

IDEAYA Biosciences stands at the forefront of precision medicine, dedicated to the development of targeted therapies for cancer treatment. By leveraging its deep expertise in drug discovery and bioinformatics, IDEAYA not only focuses on the development of therapeutics but also aims to create transformative cancer treatments tailored to genetic disease drivers. The company's robust pipeline includes innovative approaches like synthetic lethality and antibody-drug conjugates, making significant strides in the realm of oncology.

The mission of IDEAYA is clear: to deliver next-generation therapies that are effective, selective, and personalized for patients battling cancer, ultimately leading to improved clinical outcomes and changing the landscape of oncology.

Forward-Looking Statements

This announcement includes forward-looking statements related to IDEAYA’s participation in investor events. The company does not commit to updates regarding these statements, and investors are encouraged to review IDEAYA’s filings with the U.S. Securities and Exchange Commission for more detailed information on risks associated with their business.

Conclusion

As IDEAYA prepares to engage the investor community this September, the anticipated discussions around their innovative pipeline and long-term strategies will be key to understanding the company’s trajectory in the evolving oncology landscape. Stakeholders and investors alike will have the opportunity to gain critical insights during these events.